03 Jan Anocca

Anocca is leveraging its innovative platform approach to develop transformative T Cell Receptor (TCR) engineered-T cell (TCR-T) immunotherapies to treat solid tumours. The company has validated and deployed a proprietary precision biology platform that enables assumption-free discovery of targets and fully characterised TCRs at an industrial scale with unmatched speed and precision. Anocca has a fully integrated R&D infrastructure, underpinned by tailor-made advanced software solutions, and complemented by an in-house clinical manufacturing and process development facility. The platform has generated a broad preclinical pipeline of asset libraries with blockbuster potential and expects to progress to the clinic in the near term. Founded in 2014, Anocca is led by an experienced management team that has raised over USD 125 million in funding from a small group of investors that includes the European Investment Bank. Anocca’s team of around 100 employees operate from its site in Södertälje, Sweden. www.anocca.com